Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL: TNX-102 SL for Long COVID Pain
NCT05472090Phase 2Completed
- Sponsor
- Tonix Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-acute sequelae of SARS-CoV-2 infection (PASC) comparing TNX-102 SL 5.6 mg with Placebo (2 arms). Primary endpoint: Daily Diary Pain Numerical Rating Scale at 14 weeks. Started Aug 2022; status: completed.
02
Drugs
Tonmya
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT05472090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472090.